Generic Stay May Be Shortened Based Only On Behavior In Trial – Appeals Court

The 30-month stay of approval on generic products may be shortened if the brand firm delays responding to a patent infringement action, but not for delays in the resolution of the overall patent dispute, the Court of Appeals for the Federal Circuit found

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet